Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장준 | * |
dc.date.accessioned | 2016-08-28T12:08:21Z | - |
dc.date.available | 2016-08-28T12:08:21Z | - |
dc.date.issued | 2010 | * |
dc.identifier.issn | 0264-410X | * |
dc.identifier.other | OAK-6643 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/220848 | - |
dc.description.abstract | Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract disease in infancy and early childhood. Despite its importance as a pathogen, there is no licensed vaccine against RSV. The fusion (F) protein of RSV is a potentially important target for protective antiviral immune responses. Here, we studied the immune responses elicited by recombinant replication-deficient adenovirus (rAd)-based vaccines expressing the soluble F1 fragment of F protein (amino acids 155-524) in murine model. The expression of secreted F1 fragment by rAd was significantly increased by codon optimization. Strong mucosal IgA response was induced by single intranasal immunization of codon-optimized vaccine, rAd/F1co, but not by rAd/F1wt. A single intranasal immunization with rAd/F1co provided potent protection against subsequent RSV challenge. Interestingly, neither serum Ig nor T-cell response directed to F protein was detected in the rAd/F1co-immune mice, suggesting that protective immunity by rAd/F1co is mainly mediated through mucosal IgA induction. Indeed, co-delivery of cholera toxin B subunit significantly enhanced mucosal IgA responses by the optimized vaccine, which correlates with protective efficacy. Taken together, our data demonstrate that a single intranasal administration of rAd/F1co is sufficient for the protection and represents a promising prophylactic vaccination regimen against RSV infection. © 2010 Elsevier Ltd. All rights reserved. | * |
dc.language | English | * |
dc.title | Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection | * |
dc.type | Article | * |
dc.relation.issue | 22 | * |
dc.relation.volume | 28 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 3801 | * |
dc.relation.lastpage | 3808 | * |
dc.relation.journaltitle | Vaccine | * |
dc.identifier.doi | 10.1016/j.vaccine.2010.03.032 | * |
dc.identifier.wosid | WOS:000278877900009 | * |
dc.identifier.scopusid | 2-s2.0-77952552645 | * |
dc.author.google | Kim S. | * |
dc.author.google | Jang J.-E. | * |
dc.author.google | Yu J.-R. | * |
dc.author.google | Chang J. | * |
dc.contributor.scopusid | 장준(8735999100) | * |
dc.date.modifydate | 20231120165756 | * |